

IMPACT OF DERMATOLOGICAL TOXICITIES ON QUALITY OF LIFE IN BREAST CANCER PATIENTS EXPOSED TO ADJUVANT ENDOCRINE THERAPY

Cheryl Barry², Vincent Sibaud¹, Kautar Tagdichti⁴, Gautier Doat³; Aline Stennevin³

¹Oncodermatology Department, Cancer University Institute, Toulouse Oncopole, Toulouse, France., ²Pierre Fabre Dermo-Cosmetics, Parsippany, NJ, USA, ³Laboratoires Dermatologiques Avène, Pierre Fabre Dermo-Cosmetics & Personal Care, Laval, France, ⁴Laboratoires Pierre Fabre, Boulogne, France

INTRODUCTION

The **BCARE** (Breast Cancer Adjuvant Real-world Evaluation of dermatological adverse events) study is an international, cross-sectional and non-interventional study. This study aims to evaluate the impact of dermatological toxicities on the quality of life (QoL) in patients with early-stage breast cancer (EBC) treated with adjuvant endocrine therapy¹⁻².


The development of skin side effects, such as skin inflammation, hair/nail changes, and dry skin, and their potential impact on patients' physical, functional, emotional, and social well-being has not been studied until now. While anticancer therapies have improved in efficacy, the management of dermatological toxicities still poses a considerable challenge³.

METHODOLOGY

Targeted population: A total of 156 female patients aged 18 and older with early breast cancer undergoing adjuvant endocrine monotherapy initiated 2 to 3 years ago
Visits: During a single visit, the patient is required to complete four questionnaires: DLQI, Skindex-16, Hairdex and ItchyQoL
Investigators centers: Four countries (France, Italy, Spain and Greece) and nine centers are involved.

RESULTS

RECRUITMENT CURVE to date



SITES INVOLVED

4 countries, 9 sites. 
 Investigators are all part of the ENCADO (European Network for Cutaneous Adverse events to Oncologic Drugs) network: a European group of experts on the cutaneous toxicity of anti-cancer drugs



Pr SIBAUD
Dr LESAGE



Dr FREITES-MARTINEZ
Dr SEGURA



Dr STARACE
Pr SOLLENA
Pr FATTORE



Dr APALLA
Dr NIKOLAOU

CONCLUSIONS

The BCARE study aims to provide a comprehensive understanding of the potential impact of dermatological toxicities on the QoL of EBC patients undergoing adjuvant endocrine therapy. The results will help develop improved and widely available preventive strategies, contributing to optimal and comprehensive care of cancer patients.

The data from the BCARE study will be the first structured supportive oncodermatology data in this specific population.

Toplines results are expected in APRIL 2026

¹-Diana, A., and al. (2021). Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. Curr Treat Options Oncol, 22, 45.

²-Ferreira, M.N and al. (2019). Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol, 5, 285-307.

³-Lacouture, M. and al. (2008). Cutaneous toxicities of targeted cancer therapies. Community Oncology, 5.